Over 90 Total Lots Up For Auction at One Location - WA 04/08

Xenex to showcase LightStrike, non-mercury UV HAI reduction technology, at Knowlex conference in UK

Press releases may be edited for formatting or style | February 14, 2017 Infection Control

Dr. Mark Stibich, co-founder and Chief Scientific Officer of Xenex, will present a workshop “No-Touch Disinfection: The New Frontier in Patient Safety” during the conference, where he will review current methods for no-touch disinfection for the hospital environment with a focus on evidence for clinical outcomes.

“Antibiotic resistance and HAIs are real threats today – in the UK and around the world. But when you remove the pathogens from the patient environment, infections and antibiotic use are reduced. We want hospital professionals to understand best practices for implementing UV disinfection in their facilities to stop the transmission of HAIs and enhance patient safety,” said Dr. Stibich.

For more information on the 2017 Infection Prevention and Control conference, visit http://www.infectioncontrol2017.co.uk/

LightStrike is designed for speed, effectiveness and ease of use, which allows hospital cleaning staff to operate the robot without disrupting hospital operations. With a four- or five-minute disinfection cycle (depending on robot model), the robot can disinfect 30-62 hospital rooms per day (according to Xenex customers), including patient rooms, operating rooms, equipment rooms, emergency rooms, intensive care units and public areas. More than 400 hospitals, Veterans Affairs, Department of Defense, skilled nursing, ambulatory surgery centers and long-term acute care facilities in the U.S., Africa, Canada, UK and Europe use Xenex robots for room disinfection.


Xenex Disinfection Services
Xenex's patented Full SpectrumTM pulsed xenon UV room disinfection system is used for the advanced disinfection of healthcare facilities. Due to its speed and ease of use, the Xenex system has proven to integrate smoothly into hospital cleaning operations. Xenex's mission is to save lives and reduce suffering by eliminating the deadly microorganisms that cause hospital acquired infections (HAIs). The company is backed by well-known investors that include Malin Corporation, Battery Ventures, Targeted Technology Fund II, Tectonic Ventures and RK Ventures. For more information, visit Xenex.com.

Back to HCB News

You Must Be Logged In To Post A Comment